IOF LogoIOF World Congress on Osteoporosis 2004, May 14-18, 2004, Rio de Janeiro, Brazil
IOF Website  |  IOF World Congress 2006
Your Account: Log in or Register
Congress Homepage
Scientific Committee
Scientific Program
Press releases
Exhibitors / Sponsors
Version Española
Versão Portuguêsa

The IOF World Congress on Osteoporosis website is supported by an unrestricted educational grant from Pfizer

Pfizer

Exhibitors

Booth: N° 4 (Area A)

Company Showcase

Innovative Research To Develop Breakthrough Osteoporosis Medicines

At Lilly, we are investing significant talent and capabilities in osteoporosis research and development to make the most of an ongoing scientific revolution that promises incredible advances in health care. As an industry leader in investment for research and development of new products, Lilly has succeeded in creating innovative new osteoporosis medicines. And we have impressive products in the pipeline that also show promise in treating this devastating disease. Lilly developed and brought to market raloxifene HCL, a first-in-class selective estrogen receptor modulator (SERM), which is a non-hormonal compound that prevents osteoporosis by slowing the thinning of bone that occurs after menopause and helps prevent osteoporosis-related fractures. Since its introduction in 1998, more than 26 million prescriptions have been filled for raloxifene in more than 64 countries. Lilly's commitment to osteoporosis research and development has also led to the introduction of teriparatide (rDNA origin) injection, the first in a new class of osteoporosis drugs called bone-formation agents. Teriparatide works by targeting cells called osteoblasts that form new bone by increasing the number and activity level of these cells. This new medical breakthrough is an important development in treating severe and established osteoporosis.

 

Back to:

Company Profile
Floor plan
Exhibitors and Sponsors

Page Top

© 2004 International Osteoporosis Foundation Web design and programming by Zephir Software Design